Incyte Receives Consensus Rating of “Buy” from Analysts (NASDAQ:INCY)
Shares of Incyte (NASDAQ:INCY) have been given a consensus recommendation of “Buy” by the sixteen ratings firms that are presently covering the company, American Banking News.com reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $62.33.
Shares of Incyte (NASDAQ:INCY) opened at 51.36 on Wednesday. Incyte has a 52 week low of $26.45 and a 52 week high of $70.86. The stock has a 50-day moving average of $49.86 and a 200-day moving average of $54.47. The company’s market cap is $8.650 billion.
Incyte (NASDAQ:INCY) last released its earnings data on Thursday, July 31st. The company reported ($0.22) EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.05 by $0.27. The company had revenue of $99.58 million for the quarter, compared to the consensus estimate of $140.72 million. During the same quarter in the prior year, the company posted $0.05 earnings per share. The company’s quarterly revenue was down 2.1% on a year-over-year basis. On average, analysts predict that Incyte will post $-0.36 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Incyte in a research note on Tuesday, August 5th. They now have a $51.00 price target on the stock. Separately, analysts at Nomura reiterated a “buy” rating on shares of Incyte in a research note on Thursday, July 24th. They now have a $90.00 price target on the stock. Finally, analysts at Nomura reiterated a “buy” rating on shares of Incyte in a research note on Monday, June 2nd. They now have a $90.00 price target on the stock.
Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.